<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643578</url>
  </required_header>
  <id_info>
    <org_study_id>Ivax-65307</org_study_id>
    <nct_id>NCT00643578</nct_id>
  </id_info>
  <brief_title>Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay</brief_title>
  <official_title>A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether a difference between two doses of formoterol
      can be detected by methacholine challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the screening visit, subjects'vital signs (heart rate, blood pressure and temperature)
      will be measured and they will perform standard spirometry. If the results of this test are
      70% of normal or greater, they will be examined by a physician, and blood (1 teaspoonful) and
      urine will be collected for routine laboratory tests (CBC and routine urinalysis). If they
      are a female, a pregnancy test will be performed.

      During the second visit, subjects will inhale 1 or 2 doses of formoterol, (Foradil Aerolizer
      12 mcg/capsule) a long-acting bronchodilator and 1 hour later, perform a methacholine test.

      At the end of the methacholine test, they will be given albuterol to reverse the effects of
      methacholine. On the third study day, they will repeat the second visit but with the opposite
      dose of Foradil.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-dose PC20</measure>
    <time_frame>3-7 days after visits 1 and 2</time_frame>
    <description>The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>1 hour after dose</time_frame>
    <description>The forced expiratory volume in the first second, expressed as a percent predicted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose of 24 mcg of formoterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose of 12 mcg of formoterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol</intervention_name>
    <description>a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol</intervention_name>
    <description>a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dry Powder Inhaler (Twisthaler)</intervention_name>
    <description>subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking male or female 18 60 years of age, with a previous diagnosis of asthma
             that has been stable for at least 4 weeks and which is unlikely to exacerbate during
             the study because of, for example, seasonal allergen exposure. Women of childbearing
             age must not be pregnant or nursing, and must be using an acceptable method of
             contraception.

          -  Ability to perform ATS/ERS-acceptable and reproducible spirometry7

          -  Screening FEV1 ≥70% of predicted for height, age, sex, and race when short-acting
             inhaled bronchodilators are withheld for at least 6 hours

          -  At least a 20% decrease in FEV1 after inhaling ≤4 mg/mL of methacholine (i.e., a PC20
             FEV1 ≤4 mg/mL)

          -  Can be taught to use the dry powder device in accordance with the product's medication
             guide.

          -  If using an oral inhaled or intranasal corticosteroid, dosage must be stable for at
             least 4 weeks.

        Exclusion Criteria:

          -  Allergy or sensitivity to inhaled methacholine, formoterol or to other β2 agonists

          -  Intolerance to other components of the inhaler or sensitivity to milk proteins

          -  Cigarette smoking in past year or &gt;10 pack-year smoking history

          -  Respiratory tract infection within the last four weeks

          -  History of severe asthma attack requiring hospitalization in the previous 12 months

          -  Short course of oral and/or systemic corticosteroids in the past 4 weeks

          -  Inability to withhold caffeinated beverages for 12 hours or medications for
             appropriate intervals prior to each methacholine challenge

          -  Require treatment with beta-blockers (administered by any route), MAO inhibitors,
             tricyclic antidepressants, and/or maintenance therapy with systemic corticosteroids

          -  History and/or presence of pulmonary conditions (including but not limited to cystic
             fibrosis and bronchiectasis) other than asthma

          -  History of clinically-significant cardiovascular, renal, neurologic, liver or
             endocrine dysfunction. Patients with well-controlled hypertension,
             hypercholesterolemia or diabetes will not be excluded.

          -  If female, a positive urine β-HCG test

          -  Known or suspected substance abuse (e.g., alcohol, marijuana, etc.) and/or any other
             medical or psychological conditions that in the investigator's opinion should preclude
             study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Hendeles, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Asthma Research Lab</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol. 1987 Jun;79(6):876-82.</citation>
    <PMID>3294976</PMID>
  </reference>
  <reference>
    <citation>Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. Chest. 1992 Feb;101(2):309-15.</citation>
    <PMID>1310456</PMID>
  </reference>
  <reference>
    <citation>Hendeles L, Beaty R, Ahrens R, Stevens G, Harman EM. Response to inhaled albuterol during nocturnal asthma. J Allergy Clin Immunol. 2004 Jun;113(6):1058-62. Erratum in: J Allergy Clin Immunol. 2006 Apr;117(4):773.</citation>
    <PMID>15208585</PMID>
  </reference>
  <reference>
    <citation>Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O'Byrne PM, Hargreave FE. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am J Respir Crit Care Med. 1999 Jul;160(1):354-7.</citation>
    <PMID>10390425</PMID>
  </reference>
  <reference>
    <citation>Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, Lux C, Han SH. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. Am J Respir Crit Care Med. 1999 Oct;160(4):1238-43.</citation>
    <PMID>10508813</PMID>
  </reference>
  <reference>
    <citation>Creticos PS, Adams WP, Petty BG, Lewis LD, Singh GJ, Khattignavong AP, Molzon JA, Martinez MN, Lietman PS, Williams RL. A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. J Allergy Clin Immunol. 2002 Nov;110(5):713-20.</citation>
    <PMID>12417879</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999 Jan;159(1):179-87.</citation>
    <PMID>9872837</PMID>
  </reference>
  <reference>
    <citation>Asmus MJ, Vaughan LM, Hill MR, Chesrown SE, Hendeles L. Stability of frozen methacholine solutions in unit-dose syringes for bronchoprovocation. Chest. 2002 May;121(5):1634-7.</citation>
    <PMID>12006455</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <results_first_submitted>August 5, 2011</results_first_submitted>
  <results_first_submitted_qc>November 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2011</results_first_posted>
  <last_update_submitted>November 29, 2011</last_update_submitted>
  <last_update_submitted_qc>November 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>formoterol</keyword>
  <keyword>methacholine challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between April and November, 2008, the UF Asthma Research Lab recruited 37 patients for study.</recruitment_details>
      <pre_assignment_details>Of the 37 subjects who signed informed consent, 25 did not meet inclusion/exclusion criteria. The provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second (PC20FEV1) was not less than or equal to 4 mg/mL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Formoterol 12 First</title>
          <description>a single dose of 12 mcg of formoterol was given first, then 24 mcg of formoterol</description>
        </group>
        <group group_id="P2">
          <title>Formoterol 24 First</title>
          <description>a single dose of 24 mcg of formoterol was given first, then 12 mcg of formoterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>A single dose of 12 mcg and 24 mcg, on separate days, of formoterol were given.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-dose PC20</title>
        <description>The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.</description>
        <time_frame>3-7 days after visits 1 and 2</time_frame>
        <population>Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.</population>
        <group_list>
          <group group_id="O1">
            <title>12 Mcg Formoterol</title>
            <description>low dose</description>
          </group>
          <group group_id="O2">
            <title>24 Mcg Formoterol</title>
            <description>high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PC20</title>
          <description>The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.</description>
          <population>Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.</population>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="22"/>
                    <measurement group_id="O2" value="16" lower_limit="5" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1</title>
        <description>The forced expiratory volume in the first second, expressed as a percent predicted.</description>
        <time_frame>1 hour after dose</time_frame>
        <population>Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.</population>
        <group_list>
          <group group_id="O1">
            <title>12 Mcg of Formoterol</title>
            <description>low dose</description>
          </group>
          <group group_id="O2">
            <title>24 Mcg of Formoterol</title>
            <description>high dose</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1</title>
          <description>The forced expiratory volume in the first second, expressed as a percent predicted.</description>
          <population>Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.</population>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="12"/>
                    <measurement group_id="O2" value="91" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Formoterol 12</title>
          <description>A single dose of 12 mcg of formoterol was administered.</description>
        </group>
        <group group_id="E2">
          <title>Formoterol 24</title>
          <description>A single dose of 24 mcg of formoterol was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leslie Hendeles</name_or_title>
      <organization>University of Florida Asthma Research Lab</organization>
      <phone>352-273-6027</phone>
      <email>hendeles@cop.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

